Researchers led by Nobel Laureate David Baker have developed novel AI methods to design protein binders targeting intrinsically disordered regions (IDRs) of proteins, which traditionally represent over half of the human proteome and were considered 'undruggable.' These sequence-based approaches do not require structural data and enable binding to flexible protein regions involved in diseases including cancer and pain. Their recent work demonstrated binders with strong affinity to IDRs implicated in opioid signaling, DNA repair, and diabetes-related amyloid formation, marking a significant expansion in drug discovery targets and capabilities.